Physiogenex S.A.S. Physiogenex is a renowned preclinical contract research organization (CRO) specializing in metabolic and cardiovascular diseases . In this focused niche market we provide integrated preclinical and scientific consultancy services to optimize drug discovery development and shorten the time to market for new targets and compounds. Our in-house capabilities and innovative customized solutions, combined with our scientific team expertise, provide our partners with reliable and long-lasting R&D collaborations. We offer the following services: Discovery : Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision Preclinical development : In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs Marketing : Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning Physiogenex pioneers the development of radiolabeled tracer-based kinetic methods and predictive animal nutritional models . We thus provide our partners with pertinent and reliable discovery and preclinical data for successful strategic decision-making . Physiogenex has rapidly achieved global player status by virtue of its unique expertise, covering complex metabolic disorders associated with diabetes , obesity , lipid disorders (dyslipidemia, hypercholesterolemia) and liver disorders ( NASH / NAFLD ), hypertension and cardiovascular diseases . Physiogenex is an entrepreneurial, science-driven company dedicated to helping pharmaceutical, biotechnology and nutraceutical companies.